TheranosticTrials.org

Clinical Trial · NCT03699332

Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin

Overview

Intraoperative tumor localization and resection can be enhanced using intraoperative fluorescence imaging and radiodetection. Labetuzumab specifically recognizes CEA which is is expressed on \> 95% of colorectal cancers.. Therefore Indium-111-DOTA-labetuzumab-IRDye800CW is a perfect dual-labeled antibody for dual-modality image-guided surgery in peritoneal carcinomatosis of colorectal cancer.

Sponsor

Radboud University Medical Center

Phase

Phase 1/2

Contacts

JM de Gooyer, MD (CONTACT)

jan-marie.gooyer@radboudumc.nl

0031 24 3667244

FMK Elekonawo, MD (CONTACT)

fortune.elekonawo@radboudumc.nl

0031 24 3619097

JHW de Wilt, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03699332

Drug / Compound

labetuzumab-IRDye800CW

Isotope(s):
Target(s):
  • CEA
Ligand Class: Antibodies
Chelator: DOTA

Eligibility

Inclusion

  • Clinical diagnosis of peritoneal carcinomatosis of colorectal origin
  • Scheduled for cytoreductive surgery and HIPEC.

Exclusion

  • Known CEA negative tumor
  • Any medical condition present that in the opinion of the investigator will affect patients clinicals status
  • Pregnancy or lactation
  • Patients with very high (\>500ng/ml serum CEA levels
  • Administration of a radionuclide within 10 physical half-lives prior to study enrollment